IPP Bureau
Alkem ‘Healthy Lungs' initiative aims to clear the air
By IPP Bureau - October 31, 2023
The initiative will focus on advocating for cleaner air
Lubrizol launches carbopol polymers for nutraceuticals with new EU good grade approval
By IPP Bureau - October 31, 2023
The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
By IPP Bureau - October 30, 2023
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
EnginZyme produces key mRNA vaccine ingredient using biocatalysis
By IPP Bureau - October 30, 2023
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Tanaka develops first high entropy precious metals alloy powder
By IPP Bureau - October 30, 2023
With the establishment of five different precious metals alloy powder production methods
Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
By IPP Bureau - October 30, 2023
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
By IPP Bureau - October 30, 2023
The companies plan to start a pivotal Phase 3 trial in the coming months
Mandaviya inaugurates Rural Health Training Centre (RHTC) Hospital in Najafgarh, Delhi
By IPP Bureau - October 26, 2023
RHTC will address a long-standing healthcare access issue for all the local population
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer
By IPP Bureau - October 26, 2023
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
By IPP Bureau - October 26, 2023
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Venus Remedies earns REO Certification from CII for second consecutive year
By IPP Bureau - October 26, 2023
The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
Lilly's Retevmo phase 3 results in RET fusion-positive non-small cell lung cancer
By IPP Bureau - October 26, 2023
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
BASF Pharma Solutions introduces premium services to its VPAs digital services platform
By IPP Bureau - October 25, 2023
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Innocan Pharma reports discovery regarding its LPD platform and global CBD research
By IPP Bureau - October 25, 2023
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Nanoform grant global starmap AI license to AstraZeneca
By IPP Bureau - October 25, 2023
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
